Document is current
Any future updates will be listed below
-
Authors
Rossiello, Francesca https://orcid.org/0000-0002-6240-9907
Jurk, Diana https://orcid.org/0000-0003-4486-0857
Passos, João F. https://orcid.org/0000-0001-8765-1890
d’Adda di Fagagna, Fabrizio https://orcid.org/0000-0002-9603-5966
- License Information
-
More Information
Article History
Received: 24 May 2021
Accepted: 6 January 2022
First Online: 14 February 2022
Competing interests
: F.R. and F.d’A.d.F. are inventors on the patent applications PCT/EP2013/059753 and PCT/EP2016/068162. J.F.P. and D.J. declare no competing interests. I.F.O.M. has applied for European and US patent applications (EP 13721970.5, US 14/400,131 and 15/476,800), covering the use of antisense oligonucleotides targeting RNA species generated at the site of DNA damage, and for AU, BR, CA, CN, EA, EP, JP, KR, MX and US patent applications (AU2016300141, BR1120180017825, CA 2993128, CN 2016800566045, EA 201890379, EP 16750690.6, JP 2018504223, KR 20187005777, MX/A/2018001126, US 15/748,133 and US 17/065,409), covering the use of antisense oligonucleotides for the treatment of cancer characterized by alternative lengthening of telomeres and non-cancer conditions associated with telomere dysfunction, that list F.d’A.d.F. and F.R.
